my country's new crown vaccine has accumulated nearly 2.4 billion doses, experts respond to hot issues

　　my country started to vaccinate the new crown vaccine in December last year. So far, the cumulative number of new crown vaccines has been close to 2.4 billion doses, and the coverage rate of the whole population is the world's leading.

Clinical research results show that my country's new crown vaccine has good safety and effectiveness.

Zheng Zhongwei, the leader of the vaccine research and development team of the State Council's Joint Prevention and Control Mechanism Research Team, responded to some hot issues on vaccination in an exclusive interview with CCTV reporters.

my country's new crown vaccine has good safety and effectiveness

　　At present, 13 new crown vaccines in my country have entered phase III clinical trials, 4 new crown vaccines have been approved for conditional marketing, and 3 new crown vaccines have been approved for emergency use. The research and development and production of vaccines have always been in the world's first phalanx.

At the same time, my country has taken the new crown vaccine as a global public product and has provided more than 1.7 billion doses of the new crown vaccine to more than 110 countries and international organizations.

Zheng Zhongwei, Head of the Vaccine R&D Special Team of the Joint Prevention and Control Mechanism Research Team of the State Council:

China's new crown vaccine has made China's contribution to the global new crown epidemic prevention and control, and is set by the WHO to achieve the global vaccination target by the end of this year and next year China has made its due contribution to achieving the global vaccination target.

　　Clinical research results show that my country's new crown vaccine has good safety and low side effects in the more than 1 billion doses of vaccination in high-endemic countries abroad and more than 2 billion doses of vaccination in China. For example, the proportion of fever after vaccination is 17.61/100 In general, no treatment is required; severe allergic reactions are less than one in ten million, and there is no major problem as long as they are treated in time.

In general, the safety indicators of the new crown vaccine currently vaccinated in my country are better than the various vaccines vaccinated in normal years.

my country's new crown vaccine has a significant effect in preventing severe illness and death

　　Research data at home and abroad has proved that my country's new coronavirus vaccine has a certain effect on preventing infection, has a significant effect on preventing severe illness and death, and has a protective effect on various mutant strains.

　　Zheng Zhongwei believes that human history of controlling infectious diseases such as smallpox, measles, and diphtheria shows that vaccines are the ultimate weapon to defeat infectious diseases.

Foreign real-world studies have verified the effectiveness of my country's new crown vaccine.

A consultant from the Chilean Ministry of Health recently published in the New England Journal of Medicine the world’s largest real-world study of the new crown vaccine for 10 million people. The results showed that 14 days after the second dose of Coxingzhongwei inactivated vaccine, the overall protection was 65.9. %, the protection against hospitalization, severe illness and death were 87.5%, 90.3% and 86.3%, respectively.

According to a report from the Peruvian Ministry of Health, 60,593 doctors were vaccinated with the Sinopharm China Bio-New Crown Inactivated Vaccine. Among them, the death rate after two doses of vaccination was reduced by 98%.

The Ministry of Health of Argentina issued a report stating that two doses of Sinopharm's China Bio-New Crown Inactivated Vaccine has an overall mortality protection rate of 84% for people over 60 years of age.

The Sri Lankan research report on the effectiveness of the Sinopharm China Bio-New Crown Inactivated Vaccine showed that the antibody titer of the vaccine recipients against the Delta strain only dropped by 1.38 times, which still has a good protective effect against the Delta strain.

Zheng Zhongwei

,

In China, some of the epidemics that occurred last year and this year can also make such judgments.

Since the outbreak in Guangdong in May and June this year, the main virus strain circulating in our country is the Delta strain. From Guangdong, Jiangsu, Fujian to Inner Mongolia, Gansu, Qinghai, etc., although there are more outbreaks, the number of people we have infected is severely ill. The number of people is completely two concepts from the epidemic in Xinfadi, Beijing and Gaocheng, Shijiazhuang, Hebei last year.

Therefore, the country has rapidly promoted large-scale population vaccination from this year, and it should be said that it has played a very important role.

　　Zheng Zhongwei introduced that domestic real-world studies have also verified the effectiveness of my country's new crown vaccine.

In Jiangsu and other places, as of August 25, a total of 1,388 cases of infection have been reported, all infected with the Delta strain.

According to preliminary analysis, only 5 of the infected patients 14 days after the two doses of vaccination developed into severe illness, accounting for about 5% of all severe cases, and 97% of severe cases over 60 years of age did not receive the vaccination or did not complete the two doses of vaccination.

A study on the protective effect of vaccines in the Guangdong epidemic led by Academician Zhong Nanshan showed that the protective effect of the two inactivated vaccines of Sinopharm Zhongsheng and Kexing Zhongwei to prevent moderate new coronary pneumonia can reach 70.2%, and the protective effect of severe cases is up to 100%.

Even if it develops into a severe illness, most patients who have been vaccinated can become normal in a short period of time.

my country has completed the preclinical study of the delta strain inactivated vaccine

　　At present, various vaccine research and development units have carried out a series of work on various variant strain vaccines, among which the preclinical research of the delta strain inactivated vaccine has been completed.

　　Real-world studies have shown that my country’s vaccines have clear effects on infections caused by various major variant strains circulating in different regions and re-transmission after infection, and have significant effects on the prevention of severe illness and death.

On the whole, the mutation of the new coronavirus is relatively stable.

Judging from the recent domestic outbreaks, domestic vaccines are still effective against the Delta strain.

However, in order to be prepared, each vaccine research and development unit has carried out a series of work on various variant strain vaccines.

　　At present, the preclinical studies of the Gamma strain and Delta strain inactivated vaccines have been completed, and some units have submitted clinical trial application materials to the Food and Drug Administration; some units are carrying out preclinical studies of bivalent vaccines; at the same time, they have carried out research on different mutant strains. For the research of broad-spectrum or multivalent recombinant protein vaccines, some units have also submitted clinical trial application materials to the Food and Drug Administration on a rolling basis; developed adenovirus vector vaccines and nucleic acid vaccines against Beta strains and Delta strains, and some units have completed animal effects Sex and safety trials are preparing to apply for clinical trials.

Relevant institutions have preliminarily formulated guidelines for the development and evaluation of vaccines against mutant strains. Once a serious mutant strain appears, a vaccine against the mutant strain can be quickly put into production.

Zheng Zhongwei

,

At present, it seems that after our existing vaccination against the Delta strain, especially after the enhanced vaccination, the effect is clear.

So we are now prepared for the research on mutant viruses, but we don’t need it for the time being.